The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2022

Filed:

Jul. 11, 2017
Applicant:

Paul Scherrer Institut, Villigen Psi, CH;

Inventors:

Philipp Rene Spycher, Zurich, CH;

Martin Behe, Gelterkinden, CH;

Roger Schibli, Baden, CH;

David Hurwitz, Zurich, CH;

Olivier Kreis, Frick, CH;

Assignee:

PAUL SCHERRER INSTITUT, Villigen, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 11/089 (2020.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); C12P 21/00 (2006.01); C12N 11/00 (2006.01); C12N 9/10 (2006.01); C07K 14/195 (2006.01); A61K 47/69 (2017.01); A61K 47/60 (2017.01); C07K 16/18 (2006.01);
U.S. Cl.
CPC ...
C12N 11/089 (2020.01); A61K 47/60 (2017.08); A61K 47/64 (2017.08); A61K 47/6811 (2017.08); A61K 47/6887 (2017.08); A61K 47/6937 (2017.08); C07K 14/195 (2013.01); C07K 16/18 (2013.01); C12N 9/1044 (2013.01); C12N 11/00 (2013.01); C12P 21/00 (2013.01); C12Y 203/02013 (2013.01);
Abstract

Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. Solid-phase microbead-immobilization is used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. MTG remained firmly immobilized with no detectable column bleeding and enzyme activity was sustained during continuous operation. Immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted when the conjugation was carried out in solution. The generation of dual site-specifically conjugated IgG1 with immobilized and MTG in solution is reported, i.e. site-specific conjugation to glutamine and lysine residues of IgG1 antibody. Site-specific glutamine conjugation with small peptides containing a lysine residue and a functional moiety is also described.


Find Patent Forward Citations

Loading…